Abstract 250P
Background
Seminoma is the most common type of germ cell tumors representing 95% of all testicular neoplasm with mean age at diagnosis of 39 years. The standard treatment modality for stage I/II is orchidectomy with high cure rate.There is an active debate regarding the use of adjuvant therapy in stage I/II due to the high relapse rate and potential for overtreatment with serious systemic side effects. The aim of this study is to assess the impact of adjuvant treatment in stage I and stage II seminoma comparing the young and adolescents to older age groups.
Methods
Data of 11718 patients diagnosed with seminoma stage I/II were obtained from the Surveillance, Epidemiology, and End Results (SEER) program from 2000 to 2020. They were grouped by age at diagnosis into younger than 25 years (young age group), 25 to 49 years ( middle age group) and older than 50 years (old age group). SPSS 23 was used for data analysis, Kaplan-Meier curve and log rank test for survival analysis.
Results
Patients treated surgically with no systemic therapy had 5-year relative survival of 99,4% compared to adjuvant chemotherapy (98.3%) and adjuvant radiotherapy(100%), P<0.0001. The middle age group had quite similar 5-year relative survival compared to the young age group and the elderly (99.5%, 99.3% and 99%; P<0.0001). In the young age group the 5-year relative survival was 99.9% with orchidectomy, 97.4% with adjuvant chemotherapy and 100% with adjuvant radiotherapy (p <0.0001). In the middle age group, the 5-year relative survival was 99.2% with surgery with no systemic therapy, 98.4% with adjuvant chemotherapy and 99,9% with adjuvant radiotherapy (p <0.0001) while the old age group had 5-year relative survival of 98.9% for orchidectomy, 97.5% with adjuvant chemotherapy and 99.6% with adjuvant radiotherapy(p <0.0001).
Conclusions
The use of adjuvant chemotherapy and radiotherapy for clinical stage I and stage II testicular seminoma came statistically significant. However, adjuvant systemic therapy has very limited survival benefit compared to surgical management with no systemic therapy which discourage the use of adjuvant therapy for less systemic side effects with similar overall survival across different age groups.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
49P - Survival outcomes of HER2-positive breast cancer patients treated with neoadjuvant therapy at a single cancer centre in India
Presenter: Minit Shah
Session: Poster Display
Resources:
Abstract
50P - A nationwide retrospective cohort study of the response to neoadjuvant chemotherapy between HER-2 low and HER-2 negative non-metastatic breast cancer in Qatar: A real-world analysis
Presenter: Ahmed Kardousha
Session: Poster Display
Resources:
Abstract
51P - Four-year outcomes of hypofractionated postmastectomy radiation therapy of 39 Gy in 13 fractionations
Presenter: Sevinj Gahramanova
Session: Poster Display
Resources:
Abstract
52P - A comparative study to assess volumetric and dosimetric profile of heart and lung in patients undergoing left sided post mastectomy radiotherapy: Continuous positive airway pressure (CPAP) versus free breathing (FB) techniques
Presenter: Pritanjali Singh
Session: Poster Display
Resources:
Abstract
29P - HUWE1 inhibition has tumor suppressive effect in triple-negative breast cancer cell lines by modulating glycolytic and immune modulatory markers
Presenter: Shruti Kahol
Session: Poster Display
Resources:
Abstract
53P - Radiotherapy utilization rate for breast cancer in Indonesia: A call for empowering cancer care
Presenter: Donald Manuain
Session: Poster Display
Resources:
Abstract
58P - Safety and pharmacokinetics (PK) of vepdegestrant in Japanese patients with estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Results from a Japanese phase I study
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
59P - Comprehensive genomic profiling (CGP) unravels druggable targets in breast carcinoma (BC): A single institutional experience
Presenter: Gautam Balaram
Session: Poster Display
Resources:
Abstract
60P - A study of gene alterations in Asian patients with late stage and recurrent breast cancer
Presenter: Po-Sheng Yang
Session: Poster Display
Resources:
Abstract
61P - Tumor cell-released autophagosomes (TRAPs) remodel the breast tumor microenvironment by inducing the formation of inflammatory cancer-associated fibroblasts (CAFs)
Presenter: Chengdong Wu
Session: Poster Display
Resources:
Abstract